Showing results (161-170 of 398) with videos related to
Sort By:
Pageof 40
Journal of Cancer|June 23, 2017
The Clinical Impact of c-MET Over-Expression in Advanced Biliary Tract Cancer (BTC)Mi Hwa Heo, Hee Kyung Kim, Hansang Lee, et al.Journal of Oncology|March 28, 2022
Incidence of FGFR2 Amplification and FGFR2 Fusion in Patients with Metastatic Cancer Using Clinical SequencingSujin Hyung, Boram Han, Jaeyun Jung, et al.Oncology|March 17, 2021
Programmed Death Ligand 1 Expression as a Prognostic Marker in Patients with Advanced Biliary Tract CancerHyera Kim, Jinchul Kim, Seonggyu Byeon, et al.American Journal of Translational Research|August 10, 2019
Neutralizing antibody to FGFR2 can act as a selective biomarker and potential therapeutic agent for gastric cancer with FGFR2 amplificationSeung Tae Kim, In Kyoung Lee, Eran Rom, et al.Journal of Cancer Research and Clinical Oncology|September 12, 2021
The prevalence of homologous recombination deficiency (HRD) in various solid tumors and the role of HRD as a single biomarker to immune checkpoint inhibitorsHana Kim, Soomin Ahn, Hongsik Kim, et al.Medical Oncology (Northwood, London, England)|March 4, 2010
Irinotecan plus carboplatin in patients with extensive-disease small-cell lung cancerYoung Saing Kim, Se Hoon Park, Sun Young Kyung, et al.The Korean Journal of Internal Medicine|January 26, 2007
Diagnostic usefulness of the Janus kinase 2 mutation in non BCR/ABL myeloproliferative disordersSoo-Mee Bang, Jeong Yeal Ahn, Jiyoon Park, et al.Translational Oncology|March 10, 2015
Molecular Subgroup Analysis of Clinical Outcomes in a Phase 3 Study of Gemcitabine and Oxaliplatin with or without Erlotinib in Advanced Biliary Tract CancerSeung Tae Kim, Kee-Taek Jang, Jeeyun Lee, et al.BMC Cancer|April 18, 2015
Efficacy of pazopanib monotherapy in patients who had been heavily pretreated for metastatic soft tissue sarcoma: a retrospective case seriesKwai Han Yoo, Hyo Song Kim, Su Jin Lee, et al.BMC Cancer|May 24, 2012
ERCC1 as a biomarker for bladder cancer patients likely to benefit from adjuvant chemotherapyJong-Mu Sun, Ji-Youn Sung, Se Hoon Park, et al.Pageof 40